Develop cancer treatments
Join Orano Med, a subsidiary of the Orano group, to contribute to an ambitious project: to develop a new generation of targeted therapies against cancer for patients not responding to existing treatments. Targeted Alpha Therapy is a technology that combines lead-212 with biological molecules (peptides, antibodies) in order to target cancer cells. TAT can selectively recognize and destroy cancer cells, while limiting the impact on surrounding healthy cells.
180
Employees in France and the United States
12
Patented inventions
2
Clinical trials underway
2
Pre-clinical laboratories dedicated to the development of alpha therapies
It's an honor to be able to contribute to the development of a drug that could change people's lives. It's a real challenge but it's also very rewarding.
Amanda, Operations Manager
The promise of Targeted Alpha Therapy
Orano Med is proud to be a pioneer in the use of lead-212, a rare radioisotope with unique properties, to develop Targeted Alpha Therapy treatments. This novel precision medicine approach aims not only to
extend the lives of patients suffering from rare cancers but also to improve their quality of life.
AlphaMedixTM, which targets neuroendocrine tumors, is Orano Med’s most advanced
candidate drug. Another candidate drug is currently the subject of a phase 1 clinical trial on different types of solid tumors with an anti-GRPR peptide as a targeting molecule.
In October 2024, Orano Med and Sanofi entered into an agreement to accelerate the development of a new generation of lead-212-based radioligand therapies (RLTs).
A reliable supply of lead-212
In addition to a substantial portfolio of molecules under development, Orano Med has a highly differentiating global industrial platform which will allow it to ensure a reliable, scalable supply of lead-212 based therapies to patients worldwide.
Orano Med has invested in the following unique facilities:
- the Laboratoire Maurice Tubiana (LMT) in Bessines (France);
- the Domestic Distribution & Purification Unit (DDPU) in Plano (Texas);
- 2 Alpha Therapy Laboratories
(ATLabs) for the production of drugs for North America (Brownsburg – Indiana) and for Europe (Valenciennes – France: opening in 2025)
I often hear people say they want to get into an area where they can help. At Orano Med, we are actively trying to beat cancer. It’s hard to imagine anything more exciting!
Aaron Schatzmann, R&D researcher and project leader, Orano Med
